83results about How to "Excessive amount" patented technology

The present invention relates to an absorbent structure, preferably for use in absorbent products, such as used in the food, consumer, household, building and construction, beauty and medical industry, and as used in the personal hygiene industry. The substantially cellulose free absorbent structures continuously immobilise absorbent polymer material via initial smaller pockets and subsequently larger compartments allowing excellent fluid management of the absorbent polymer material in dry, partially and fully liquid loaded state. Preferably such absorbent structure volume increases are result of temporary secondary attachment patterns made in combination with substantially permanent primary attachment grids allowing the release of bigger volumes from the initial smaller volumes by detachment of the secondary attachments. Furthermore the absorbent structure according to an embodiment of the invention non-homogeneously swells to form a liquid-managing surface structure as a result of exposing the absorbent structure to liquid. The present invention foresees in the need for improved flexible, thin, lightweight absorbent structures which overcome the absorbency problems of the prior art during absorption, distribution and retention of liquids with optimal fit.

A device cooperating with a pump for guiding a contrast medium from a source thereof to a catheter for delivery to a patient's vascular system. The device comprises a dual check valve, a tubular member, an in-line check valve and a three-port stopcock. The dual check valve has an inlet port connectable to the source of contrast medium, an inlet-outlet port connectable to the pump, and an outlet port coupled to the tubular member. The in-line check valve is connected to the tubular member at a point spaced from the dual check valve for preventing fluid flow towards the dual check valve. The stopcock connected at a first port to the in-line check valve, a second port of the stopcock being operatively connectable to the catheter. Using this device, medical personnel infuses contrast medium into the patient from the source without having to disconnect any element from the device during the infusion process.

A channel sounding method in a wireless local area network (WLAN) system is provided. The method, performed by a transmitter, includes transmitting a null data packet announcement (NDPA) frame to a receiver to initiate a channel sounding procedure; transmitting a null data packet (NDP) to the receiver and receiving a feedback frame. The feedback frame includes a plurality of segment frames and a channel feedback report. The channel feedback report is split into a plurality of feedback segments. Each of the plurality of feedback segments is respectively included in each of the plurality of segment frames. The each of the plurality of segment frames includes a first-segment subfield indicating whether the each of the plurality of feedback segment included is a first segment and a remaining-segment subfield indicating the number of remaining feedback segments.

Abuse resistant pharmaceutical formulations are provided that contain one or more abusable drugs and one or more abuse deterrent components. The abuse deterrent component(s) prevent the abusable drug(s) from being removed/extracted to an appreciable extent and/or rate. The abuse deterrent component(s) may be in the form of pellets, beads, beadlets, granules, powders, or the like, and may comprise a core that contains a material that is both hydrophilic and hydrophobic, and optionally a pH-dependent coating.

A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved.

Improvements in the wash durability and discoloration levels for fabrics having topically applied silver-ion treatments (such as ion-exchange compounds, like zirconium phosphates, glasses and/or zeolites) are provided. Such solid compounds are generally susceptible to discoloration and, due to the solid nature thereof, are typically easy to remove from topical surface applications. The inventive treatment requires the presence of a specific polyurethane binder, either as a silver-ion overcoat or as a component of a dye bath mixture admixed with the silver-ion antimicrobial compound. In addition, specific metal halide additives (preferably substantially free from sodium ions) are utilized to combat the discolorations typical of such silver-ion formulations. As a result, wash durability, discoloration levels, or both, can be improved to the extent that after a substantial number of standard launderings and dryings, the inventive treatment does not wear away in any appreciable amount and the color of the treatment remains substantially the same as when first applied. The particular treatment method as well as the treated fabrics are also encompassed within this invention.

A method for providing a preferred selection from menu using a customer profile, historical transaction data and environmental information is described. The method include capturing a facial image of a customer using a camera, extracting features from the facial image using a face recognition algorism running on a CPU, obtaining current environmental information from a website via computer network using a control algorism running on the CPU, storing transaction data associated with the customer in the database using a POS (Point of Sales) system, calculating a probability distribution of the preferred selection based on conditions including the customer profile, the environment information and transaction data stored in the database using the control algorism running on the CPU, and presenting the preferred selection to the customer in descending order from a largest value of probability to a lowest probability of the calculated probability distribution.

A polyester composition with reduced acetaldehyde concentration comprising polyester, at least one hydrogenation catalyst, and at least one source of reactive hydrogen. A method for making the polyester composition is also disclosed along with polyester articles made with the polyester composition. Suitable articles include containers such as bottles. A packaged beverage comprising a container made with the polyester composition is disclosed.

Adaption of signal processing for actively reducing occlusion in hearing apparatuses, and in particular in hearing aids, is to be automated further. For this purpose, a transducer transmission function, which is defined for the transmission path from the input of a receiver via the auditory canal to the output of a microphone, be subjected to an automatic plausibility check. An adjustable filter via which the microphone signal is fed back is only altered if the transducer transmission function is plausible according to a predefined criterion. Disadvantageous convergences of the adaptation algorithm can be avoided hereby and unnecessarily high computing times can be prevented.

A heat pipe heat dissipation structure includes a main body. The main body has an evaporation section, a condensation section, a chamber filled with a working fluid and at least one first capillary structure. The first capillary structure is disposed on an inner wall face of the chamber. The first capillary structure has at least one swelling capillary section. The swelling capillary section swells from a part of the first capillary structure in the evaporation section. The heat pipe heat dissipation structure is able to greatly increase heat transfer efficiency.

Improvements in the high-temperature wash durability and discoloration levels for fabrics having topically applied silver-ion treatments (such as ion-exchange compounds, like zirconium phosphates, glasses and/or zeolites) are provided. Such solid compounds are generally susceptible to discoloration and, due to the solid nature thereof, are typically easy to remove from topical surface applications, particularly when laundered at elevated temperatures. The inventive treatment requires the presence of a specific cross-linked binder, either as a silver-ion overcoat or as a padded-on component of a cross-linked binder admixed with the silver-ion antimicrobial compound. In addition, specific metal halide additives (preferably substantially free from sodium ions) may be utilized to combat the discolorations typical of such silver-ion formulations. As a result, high-temperature wash durability, discoloration levels, or both, can be improved to the extent that after a substantial number of standard launderings and dryings, the inventive treatment does not wear away in any appreciable amount and the color of the treatment remains substantially the same as when first applied. The particular treatment method, as well as the treated fabrics are also encompassed within this invention.

A chain tensioner includes a cylindrical cylinder having a closed end, a plunger slidably mounted in the cylinder, and a return spring biasing the plunger. The cylinder is formed with an oil supply passage through which hydraulic oil is introduced into a pressure chamber defined by the plunger and the cylinder. The oil supply passage has an orifice at its end portion facing the pressure chamber. A leak gap is defined between sliding surfaces of the plunger and the cylinder. A damper force is produced by viscous resistance of hydraulic oil flowing from the pressure chamber through the leak gap, and by viscous resistance of hydraulic oil flowing from the pressure chamber into the oil supply passage through the orifice.

The invention is directed to methods for treating disorders associated with hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitapide) and a fibrate (for example, fenofibrate). Co-administration of the MTP inhibitor with the fibrate produces a therapeutic benefit, for example, a reduction in the concentration of cholesterol and/or triglycerides in the blood stream, but with fewer or reduced side effects than when higher dosages of the MTP inhibitor are used during monotherapy to provide the same or similar therapeutic benefit.

The use of one or more compositions of one or more disinfecting agents at a relatively high pH to disinfect contact lenses and preserve ophthalmic lens compositions is described. Ophthalmic lens solutions containing one or more compositions of one or more disinfecting agents at a relatively high pH and methods of making and using the same are also described.

A process for manufacturing of an asymmetric hollow fibre membrane, comprising the steps of extruding a polymer solution through the outer ring slit of a hollow fibre spinning nozzle, simultaneously extruding a centre fluid through the inner bore of the hollow fibre spinning nozzle, into a precipitation bath, whereby the polymer solution contains 10 to 26 wt-% of polysulfone (PSU), polyethersulfone (PES) or polyarylethersulfone (PAES), 8 to 15 wt-% polyvinylpyrrolidone (PVP), 55 to 75 wt-% N-alkyl-2-pyrrolidone (NAP) and 3 to 9 wt-% w ater the centre fluid contains 70 to 90 wt-% N-alkyl-2-pyrrolidone (NAP) and 10 to 30 wt-% water, and the precipitation bath contains 0 to 20 wt-% N-alkyl-2-pyrrolidone (NAP) and 80 to 100 wt-% water.

A high performance liquid chromatography method used for dexrazoxane-related substances is provided, and in the method, a low-density bonding reversed-phase C18 chromatographic column resistant to pure water is employed; a gradient elution is carried out with mobile phase A and mobile phase B as eluents, the mobile phase A being a buffer, and the mobile phase B being an organic solvent; the volume percent of mobile phase A in eluents in a first stage of the gradient elution is not lower than 90%, and the duration of the first stage of the gradient elution ranges from 15˜30 minutes. By means of the analytical method, dexrazoxane is effectively separated from main impurities, and the qualities of the active pharmaceutical ingredients of dexrazoxane and the preparations thereof could be better controlled.

The invention provides a method for predicting the clinical response to a cancer vaccine in a patient having cancer, a method for determining the immune response to a cancer vaccine in a patient having cancer who has been administered a cancer vaccine, a method for determining the long-term survival in a patient having cancer, corresponding kits therefor, as well as methods of for improving the efficacy of a virus-based vaccine.

The present invention concerns an intrauterine device (100), IUD, comprising a stem element (30), a cross-member (70), and a withdrawal string (90), wherein the stem element (30) comprises a hollow (34) elongated body (32); the cross-member (70) comprises a coupling element (74) configured for dismountable attachment to the stem element (30), and one or more arms (76) attached to the coupling element (74); and the withdrawal string (90) is anchored to the cross-member (70) and is threaded through the hollow (34) of the stem element (30).